Coherus BioSciences: A High-Stakes Pivot to Oncology

After a period of significant volatility, shares of Coherus BioSciences are demonstrating renewed momentum. The biotech firm’s dramatic strategic shift to focus exclusively on oncology is now under the microscope. While recent share price gains are notable, they are underpinned by a profound corporate transformation that carries substantial risk.

A Strategic Bet on Cancer Therapeutics

The company is now betting its future entirely on cancer research. This commitment was formally signaled in May 2025 with the corporate rebranding to “Coherus Oncology.” The centerpiece of this new strategy is its flagship product, LOQTORZI. Second-quarter 2025 results showed a promising 36% quarter-over-quarter increase in LOQTORZI revenue, which reached $10 million. The long-term ambition is even more aggressive, with the company targeting $150-200 million in annual revenue from the drug by 2028. Beyond this commercial asset, Coherus is advancing two promising pipeline candidates, with key study data anticipated in the first half of 2026.

Financial Reset: A Mixed Picture

The Q2 2025 financials reveal a company in the midst of a fundamental reset. The sale of its biosimilars division provided a crucial cash infusion, leaving the company with $238 million in liquid assets—a war chest projected to fund operations into 2026. However, this positive liquidity stands in contrast to an operating loss of $44.9 million for the quarter, highlighting the ongoing challenges of the transition.

Should investors sell immediately? Or is it worth buying Coherus BioSciences?

Dodging a Delisting Scare

A major near-term crisis was averted in early September when Coherus regained compliance with Nasdaq listing requirements. The immediate threat of being delisted from the US tech market has been suspended. This relief comes after the stock traded below the critical $1 threshold for more than 30 consecutive trading days—a red flag for investors that had significantly pressured the company.

Analyst sentiment has shown some cautious optimism. The Maxim Group recently upgraded the stock to a “Buy” rating, assigning a price target of $4.00. Despite a recent surge of over 19% in a single week, the current share price of approximately $1.37 reflects lingering market skepticism, trading well below its yearly high. The central question remains whether Coherus is on the cusp of a genuine turnaround or if this is merely a temporary rebound.